EBANGA — Competitive Intelligence Brief

EBANGA (ANSUVIMAB-ZYKL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Envelope glycoprotein Metabolic

Target snapshot

EBANGA (ANSUVIMAB-ZYKL) — RIDGEBACK BIOTHERAPEUTICS.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
EBANGA TARGET	ANSUVIMAB-ZYKL	RIDGEBACK BIOTHERAPEUTICS	marketed		Envelope glycoprotein
Inmazeb	Inmazeb	ANRS, Emerging Infectious Diseases	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A, Envelope glycoprotein
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
Abreva	Abreva	University of Utah	marketed		Envelope glycoprotein
varicella zoster virus	varicella zoster virus	AstraZeneca	marketed	Live attenuated viral vaccine	Varicella zoster virus envelope glycoproteins
FUZEON [enfuvirtide]	FUZEON [enfuvirtide]	Hoffmann-La Roche	marketed	HIV fusion inhibitor	gp41 (HIV envelope glycoprotein)
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.